@article{c2697c118a1942cf82a9a6a195ff6f87,
title = "MTOR drives its own activation via SCF βTrCP-dependent degradation of the mTOR inhibitor DEPTOR",
abstract = "The activities of both mTORC1 and mTORC2 are negatively regulated by their endogenous inhibitor, DEPTOR. As such, the abundance of DEPTOR is a critical determinant in the activity status of the mTOR network. DEPTOR stability is governed by the 26S-proteasome through a largely unknown mechanism. Here we describe an mTOR-dependent phosphorylation-driven pathway for DEPTOR destruction via SCF βTrCP. DEPTOR phosphorylation by mTOR in response to growth signals, and in collaboration with casein kinase I (CKI), generates a phosphodegron that binds βTrCP. Failure to degrade DEPTOR through either degron mutation or βTrCP depletion leads to reduced mTOR activity, reduced S6 kinase activity, and activation of autophagy to reduce cell growth. This work expands the current understanding of mTOR regulation by revealing a positive feedback loop involving mTOR and CKI-dependent turnover of its inhibitor, DEPTOR, suggesting that misregulation of the DEPTOR destruction pathway might contribute to aberrant activation of mTOR in disease.",
author = "Daming Gao and Hiroyuki Inuzuka and Tan, {Meng Kwang Marcus} and Hidefumi Fukushima and Locasale, {Jason W.} and Pengda Liu and Lixin Wan and Bo Zhai and Chin, {Y. Rebecca} and Shavali Shaik and Lyssiotis, {Costas A.} and Gygi, {Steven P.} and Alex Toker and Cantley, {Lewis C.} and Asara, {John M.} and Harper, {J. Wade} and Wenyi Wei",
note = "Funding Information: We thank Alan Lau, Christoph Schorl, Zhiwei Wang and Susan Glueck for critical reading of the manuscript, Tamar Melman for help with data analysis, Jianping Jin, William Hahn and James DeCaprio for providing reagents; Michele Pagano and Yi Sun for sharing unpublished data, and members of the Wei, Harper, and Cantley labs for useful discussions. W.W. is a MLSC New Investigator. This work was supported in part by the DOD Prostate New Investigator award to W.W., and by grants from the National Institutes of Health (A.T., CA122099; W.W., GM089763; J.W.H., AG011085, GM0089877, and GM054137). D.G. is supported by Lady Tata Memorial Trust International Awards for Research in Leukemia Postdoctoral Fellowship. M.T. is supported by an A-STAR Predoctoral Fellowship. C.A.L. is the Amgen fellow of the Damon Runyon Cancer Research Foundation. J.W.H. is a consultant for Millennium Pharmaceuticals. ",
year = "2011",
month = oct,
day = "21",
doi = "10.1016/j.molcel.2011.08.030",
language = "English",
volume = "44",
pages = "290--303",
journal = "Molecular Cell",
issn = "1097-2765",
publisher = "Cell Press",
number = "2",
}